RG 7713

Drug Profile

RG 7713

Alternative Names: RG7713

Latest Information Update: 05 Nov 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Roche
  • Class Antipsychotics
  • Mechanism of Action Vasopressin 1a receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pervasive child development disorders

Most Recent Events

  • 03 Nov 2015 Efficacy data from a phase I trial in Pervasive child development disorders released by Roche
  • 02 Nov 2015 Roche completes a phase I trial for Pervasive child development disorders in USA
  • 01 Nov 2015 Phase-I clinical trials in Pervasive child development disorders in USA before November 2015 (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top